Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3388 - Nab-Paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): from randomized trials to real-life setting. Results from GIM13 - AMBRA study

Date

11 Sep 2017

Session

Poster display session

Presenters

Giorgio Mustacchi

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

G. Mustacchi1, M. Cazzaniga2, E. Bria3, G. Bisagni4, L. Biganzoli5, P. Pronzato6, S. De Placido7, E. Romagnoli8, F. Montemurro9, P. Marchetti10, M. De Laurentiis11, F. Riccardi12, A. Turletti13, A. Michelotti14, C. Natoli15, L. Livi16, L. Del Mastro17, M. Donadio18, O. Garrone19, M. Giordano20

Author affiliations

  • 1 Medical Oncology, University of Trieste-Ospedale di Cattinara, 34149 - Trieste/IT
  • 2 Medical Oncology, Università degli Studi di Milano Bicocca - Facoltà di Medicina e Chirurgia, 20900 - Monza/IT
  • 3 Medical Oncology, Ospedale Universitario Verona, 37129 - Verona/IT
  • 4 Medical Oncology, Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, 42100 - Reggio Emilia/IT
  • 5 Medical Oncology, Ospedale di Prato Sandro Pitigliani Med. Oncology Unit, 59100 - Prato/IT
  • 6 Medical Oncology, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 7 Medical Oncology, Università degli studi di Napoli "Federico II"-Dipartimento di Medicina Clinica e Chirurgia – Oncologia, Napoli/IT
  • 8 Medical Oncology, Ospedale Generale Provinciale Macerata, 62100 - Macerata/IT
  • 9 Medical Oncology, IRCCS Istituto di Candiolo, 10060 - Candiolo/IT
  • 10 Medical Oncology, Azienda Ospedaliera St. Andrea, 00189 - Roma/IT
  • 11 Medical Oncology, IRCCS Fondazione Pascale, Napoli/IT
  • 12 Medical Oncology, AO Cardarelli, Napoli/IT
  • 13 Medical Oncology, AOU S. Giovanni Battista - Molinette, torino/IT
  • 14 Medical Oncology, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 15 Medical Oncology, P.O. Clinicizzato Ss. Annunziata Universita' Degli Studi, 66100 - Chieti/IT
  • 16 Radioterapia, Azienda Ospedaliera Universitaria Careggi, Florence/IT
  • 17 Medical Oncology, IRCCS A.O.U. “SAN MARTINO” IST – Istituto Nazionale per la Ricerca sul Cancro- S.S. Sviluppo Terapie Innovative, Genova/IT
  • 18 Medical Oncology, AOU S. Giovanni Battista - Molinette, 10126 - Torino/IT
  • 19 Medical Oncology, Azienda Ospedaliera St. Croce e Carle, 12100 - Cuneo/IT
  • 20 Medical Oncology, Presidio Ospedaliero Ospedale Sant'Anna, 22100 - San Fermo della Battaglia/IT
More

Resources

Abstract 3388

Background

Two randomized studies demonstrated that Nab-P produces a significantly higher overall response rate (ORR), longer Time to Progression (TTP), and greater overall survival (OS) in ABC pts treated with second-line or greater therapy compared with patients who receive conventional Paclitaxel. However, few data are available in the real-life setting, especially for the weekly schedule (wNab-P).

Methods

AMBRA is a longitudinal cohort study, aiming to describe the choice of first and subsequent lines of treatment in HER2-ve ABC pts receiving at least one CHT (SABCS 2016, P5-15-07 & P5-14-09) in the years 2012-2015. For the present analysis, we focused on the use of Nab-P, describing efficacy results according to pts’ characteristics.

Results

So far, 791/1500 pts have been registered into the study and 107 (13.5%) received Nab-P in any line of treatment. Median age was 54 years, 88 (82.2%) had Luminal tumours. Twenty-two pts (20.6%) received Nab-P as 1st line, 48 (44.8%) as 2nd-line, the remaining as 3rd-line or greater. Most pts (47.7%) received the every 3 weeks (Q21) schedule, whereas 30 pts (28%) were treated with the weekly (wNab-P) schedule (days 1,8,15 Q28) at different doses: £100 mg/mq: 11 (10.3%), 125 mg/mq,: 15 (14%); 150 mg/mq: 4 (3.7%). The remaining received different schedules or doses. Median number of cycles received was 5 (1-17) and median duration of treatment was 3.5 months in the whole population. No difference has been observed in terms of number of cycles or duration of treatment according to the schedule.

Conclusions

Our results are similar to those obtained in randomized clinical trials and in a recent large real-life study, confirming that Nab-P is currently one of the most promising choice of treatment for ABC pts.

Clinical trial identification

Legal entity responsible for the study

Marina Elena Cazzaniga

Funding

GIM - Gruppo Italiano Mammella

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.